Article
No association between CYP3A4*22 and statin effectiveness in reducing the risk for myocardial infarction.
Pharmacogenomics - 1 Aug 2014
Leusink Maarten, de Keyser Catherine E, Onland-Moret N Charlotte, Hofman Albert, Visser Loes E, Stricker Bruno H, de Bakker Paul I W, de Boer Anthonius, van Schaik Ron H N, Maitland-van der Zee Anke Hilse
Abstract excerpt
AIM: Genetic variation has been shown to influence statin response in terms of lowering LDL cholesterol. The recently discovered CYP3A4*22 allele (defined as rs35599367) has been shown to affect statin-induced LDL cholesterol lowering. Our objective was to investigate whether this polymorphism modifies the risk reduction for myocardial infarction (MI) by statins. PATIENTS & METHODS: We analyzed the interaction...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.